Co-artemether
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Acute Uncomplicated P. Falciparum Malaria
Conditions
Acute Uncomplicated P. Falciparum Malaria
Trial Timeline
May 1, 2001 → Aug 1, 2005
NCT ID
NCT00233337About Co-artemether
Co-artemether is a approved stage product being developed by Novartis for Acute Uncomplicated P. Falciparum Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00233337. Target conditions include Acute Uncomplicated P. Falciparum Malaria.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00233337 | Approved | Completed |
Competing Products
20 competing products in Acute Uncomplicated P. Falciparum Malaria